Intangible Assets

PAVM does not show evidence of durable proprietary assets in the provided metrics, and the deeply negative ROIC/ROCE suggests any IP or know-how is not translating into peer-leading pricing power.

No 5-year margin or growth history is provided, so there is no filing-backed sign that patents, regulatory exclusivity, or brand strength are sustaining returns versus peers.

Compared with stronger healthcare peers that monetize protected platforms or approved products, PAVM appears to lack an observable intangible-asset moat that would defend margins over 5–10 years.

Switching Costs

The negative ROIC and near-zero asset turnover indicate customers are not locked in by high switching frictions that would preserve economics versus peers.

The extremely weak cash conversion cycle does not point to a recurring, embedded customer relationship that would make replacement costly or operationally disruptive.

Relative to peers with regulated workflows, installed bases, or mission-critical clinical integration, PAVM shows no evidence of meaningful retention advantages.

Network Effects

The provided data do not indicate a user, data, or ecosystem flywheel, and the negative profitability profile argues against scale-driven network reinforcement.

Unlike peers whose value rises as more providers, patients, or partners join the platform, PAVM shows no observable evidence of cross-side or direct network effects.

Without filing evidence of platform dependency or expanding participation benefits, network effects appear absent or immaterial.

Cost Advantage

A negative ROIC and very low asset turnover imply PAVM is not converting capital into output efficiently enough to suggest a structural cost edge versus peers.

The data do not show scale purchasing, manufacturing leverage, or process efficiency that would lower unit costs relative to competitors.

Compared with lower-cost peers that can sustain margins through operating leverage, PAVM appears cost-disadvantaged rather than advantaged.

Efficient Scale

The metrics do not show a concentrated market position or capacity constraint that would support efficient-scale economics versus peers.

Negative returns and minimal asset productivity suggest the business is not operating in a niche where a small number of firms can profitably serve demand with limited duplication.

Relative to peers in regulated or infrastructure-like markets, PAVM shows no evidence that market size or fixed-cost structure is protecting returns.

Overall Score

PAVM shows no observable durable moat in the provided data, because negative ROIC/ROCE and extremely low asset productivity do not support pricing power, retention, or cost leadership versus peers.